Cyclin D1, retinoblastoma, p53, and Her2/neu protein expression in preinvasive breast pathologies: Correlation with vascularity

Pathobiology

Volumn 68, Issue 3, 2000, Pages 129-136

  Heffelfinger, Sue C ^a   Yassin, Rawia ^a   Miller, Mary Ann ^a   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Breast cancer; Cyclin D1; Her2 neu; p53; Retinoblastoma

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER INVASION; CARCINOMA IN SITU; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CYCLIN D1; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MICROCIRCULATION; MIDDLE AGED; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; RECEPTOR, ERBB-2; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034489164     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055913     Document Type: Article

References (29)

1. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer
2. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5,232 patients
3. Expression of p53 protein in infiltrating and in situ breast carcinomas
4. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions
5. Molecular genetic studies of early breast cancer evolution
6. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes
7. Pathological and biological relevance of cytophotometric DNA content to breast carcinoma genetic progression
8. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer
9. Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue
10. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of the usual type are clonal, neoplastic proliferations
11. Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy
12. Molecular aspects of early stages of breast cancer progression
13. Induction of angiogenesis during the transition from hyperplasia to neoplasia
14. Demonstration and characterization of the angiogenic properties of cervical dysplasia
15. Establishing a link between oncogenes and tumor angiogenesis
16. Vascularity of proliferative breast disease and carcinoma in situ correlates with histologic features
17. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
18. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma
19. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogen-esis in human colon cancer
20. Consensus meeting: Is 'fibrocystic disease' of the breast precancerous?
21. Quantification of erbB-2/neu levels in tissue
22. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value
23. Microvessel density and distribution in ductal carcinoma in situ of the breast
24. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast
25. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia
26. Immunohistochemistry of cyclin D1 in human breast cancer
27. Prognostic value of the immunohistochemical expression of p53 in breast carcinoma. A review of the literature involving over 9,000 patients
28. Immunohistochemistry of tumor suppressor gene products
29. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues